Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 5
2004 6
2005 3
2006 1
2007 6
2008 4
2009 2
2010 3
2011 2
2012 4
2013 2
2014 2
2016 3
2017 7
2018 10
2019 8
2020 13
2021 11
2022 9
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of resistance to osimertinib.
Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Lazzari C, et al. Among authors: gregorc v. J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30. J Thorac Dis. 2020. PMID: 32642198 Free PMC article. Review.
Immunotherapeutic Advances for NSCLC.
Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M. Massafra M, et al. Among authors: gregorc v. Biologics. 2021 Oct 8;15:399-417. doi: 10.2147/BTT.S295406. eCollection 2021. Biologics. 2021. PMID: 34675481 Free PMC article. Review.
KRAS in NSCLC: State of the Art and Future Perspectives.
Cascetta P, Marinello A, Lazzari C, Gregorc V, Planchard D, Bianco R, Normanno N, Morabito A. Cascetta P, et al. Among authors: gregorc v. Cancers (Basel). 2022 Nov 4;14(21):5430. doi: 10.3390/cancers14215430. Cancers (Basel). 2022. PMID: 36358848 Free PMC article. Review.
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P, Tocci A, Palermo B, Di Carlo A, D'Ambrosio L, D'Andrea D, Di Modugno F, De Nicola F, Goeman F, Corleone G, Warren S, Paolini F, Panetta M, Sperduti I, Baldari S, Visca P, Carpano S, Cappuzzo F, Russo V, Tripodo C, Zucali P, Gregorc V, Marchesi F, Nistico P. Trono P, et al. Among authors: gregorc v. J Immunother Cancer. 2023 Aug;11(8):e006913. doi: 10.1136/jitc-2023-006913. J Immunother Cancer. 2023. PMID: 37612043 Free PMC article.
Angiogenesis inhibition in lung cancer: emerging novel strategies.
Lazzari C, Bulotta A, Damiano G, Mirabile A, Viganó M, Veronesi G, Gregorc V. Lazzari C, et al. Among authors: gregorc v. Curr Opin Oncol. 2022 Jan 1;34(1):107-114. doi: 10.1097/CCO.0000000000000807. Curr Opin Oncol. 2022. PMID: 34812193 Review.
Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
Pecciarini L, Brunetto E, Grassini G, De Pascali V, Ogliari FR, Talarico A, Marra G, Magliacane G, Redegalli M, Arrigoni G, Lazzari C, Gregorc V, Bulotta A, Doglioni C, Cangi MG. Pecciarini L, et al. Among authors: gregorc v. Cells. 2023 Apr 11;12(8):1135. doi: 10.3390/cells12081135. Cells. 2023. PMID: 37190044 Free PMC article.
Targeted Therapies in Early Stage NSCLC: Hype or Hope?
Friedlaender A, Addeo A, Russo A, Gregorc V, Cortinovis D, Rolfo CD. Friedlaender A, et al. Among authors: gregorc v. Int J Mol Sci. 2020 Aug 31;21(17):6329. doi: 10.3390/ijms21176329. Int J Mol Sci. 2020. PMID: 32878298 Free PMC article. Review.
Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities.
Lazzari C, Bulotta A, Cangi MG, Bucci G, Pecciarini L, Bonfiglio S, Lorusso V, Ippati S, Arrigoni G, Grassini G, Doglioni C, Gregorc V. Lazzari C, et al. Among authors: gregorc v. Diagnostics (Basel). 2020 Dec 15;10(12):1092. doi: 10.3390/diagnostics10121092. Diagnostics (Basel). 2020. PMID: 33333743 Free PMC article. Review.
105 results